Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.

ABSTRACT: CD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, we initiated a clinical trial with in-house produced CD19 CAR-T cells with a CD28 co-stimulatory domain. We analyzed, for the first time, differences in production features and phenotype between ALL and NHL patients. Non-cryopreserved CAR-T cells were produced from patients' peripheral blood mononuclear cells within 9 to 10 days. 93 patients with r/r ALL and NHL were enrolled under the same study. CAR-T cells of ALL and NHL patients were produced simultaneously, allowing the head-to-head comparison. All patients were heavily pretreated. Three patients dropped out

SUBMITTER: Itzhaki O 

PROVIDER: S-EPMC7061891 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature